1. From the Department of Urology, Program in Urologic Oncology and Urologic Outcomes Research Group (SP, MVM, EPE, PRC) and Department of Radiation Oncology (JLS), University of California-San Francisco/Mt. Zion Cancer Center, University of California-San Francisco, San Francisco, California, and TAP Pharmaceutical Products, Inc. (JD), Lake Forest, Illinois